Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple-dose QAX576 in idiopathic pulmonary fibrosis
2010-020688-18Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing QAX576 IV multiple-dose with Placebo IV (2 arms). Primary endpoint: Safety and tolerability of multiple intravenous dosing of QAX576. Started Jan 2011; status: terminated.
02
Drugs
dectrekumab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2010-020688-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020688-18.